The Peptide Marketing Mistakes That Draw FDA Warning Letters

What actually draws FDA enforcement against a peptide clinic? Three patterns dominate. First, selling research peptides or SARMs as “dietary supplements” when they do not meet the legal definition of a supplement, which turns them into unapproved new drugs. Second, marketing a peptide like BPC-157 for a specific use with no FDA approval behind it and no honest disclosure of that. Third, sourcing from a compounder that fails CGMP or sterility requirements, which can pull your clinic’s name into the same problem. None of these require bad intent. They usually start with copy lifted from a supplier’s site or a stronger verb than the evidence supports. This guide walks through what trips each one and the safer way to say it.

TL;DR

• “Supplement” is a legal category, not a marketing word. SARMs and most research peptides do not meet the dietary-supplement definition, so calling them supplements turns them into unapproved new drugs in the FDA’s eyes [2][5].
• An unapproved use needs honest framing. Marketing BPC-157 or similar peptides for healing, recovery, or any condition implies a drug claim the product has no FDA approval to support [2][3].
• Your compounder’s compliance is your exposure. When an outsourcing facility fails CGMP or sterility checks, clinics that promoted “safe” or “pharmacy-quality” product inherit the credibility problem [3].
• Two regulators watch this. The FDA polices whether your claims make a product an unapproved drug; the FTC polices whether health claims are substantiated and not deceptive [1][4].
• This is a screening step, not a clearance. A claim checker catches risky phrasing early. Your clinic’s physician and counsel are the final gate on what you publish.

Pattern 1: research peptides and SARMs sold as “dietary supplements”

The single most common trigger is calling a research peptide or a SARM a “dietary supplement.” Operators reach for the word because it sounds low-risk and consumer-friendly. The problem is that “dietary supplement” is a defined legal category, and SARMs and most research peptides do not fit it. The FDA has stated plainly that SARMs are not dietary ingredients and should not be in body-building products marketed that way [5]. Once a product falls outside the supplement definition and is marketed to affect the structure or function of the body, it meets the statutory definition of a “drug” under Section 201(g) of the Food, Drug, and Cosmetic Act, and without approval it is an unapproved new drug [2].

This is exactly what FDA flagged at Pinnacle Professional Research dba Pinnacle Peptides in December 2025, where SARM products including S4 Andarine, LGD-4033, and MK-2866 were marketed as dietary supplements (Atlas entry). The same month, FDA issued a letter to Musclepower Enterprise Ltd. dba MONSTER KING and GE LABS over SARMs such as “GE Labs Ykarine” and “GE Labs MK 677” sold the same way (Atlas entry). These are not edge cases. They are the template.

The safer phrasing is to stop describing these products as supplements entirely and to be accurate about their regulatory status. If a compound is administered under a physician’s care, describe it as a prescribed or compounded therapy, not a supplement, and do not attach structure-function language borrowed from the supplement world. If you cannot describe a product honestly without implying it is an approved drug or a supplement, that is a signal to pull the claim, not soften it.

Pattern 2: peptides marketed for uses with no FDA approval and no disclosure

The second pattern is marketing a peptide for a specific benefit when there is no FDA approval for that use and no disclosure of that fact. BPC-157 is the common example. Clinics describe it for tissue healing, gut repair, injury recovery, or joint health. Each of those is a claim that the product treats or affects a condition, which is drug-claim territory under Section 201(g) [2]. When the product has no approval for that use and the page does not say so, the claim reads as an implied promise the clinic cannot stand behind.

The FTC angle compounds this. Under its Health Products Compliance Guidance, health claims must be supported by competent and reliable scientific evidence before they are made, and the absence of that support is itself the violation [1]. The FTC’s Section 5 authority lets it act on deceptive or unsubstantiated health claims directly [4]. So a single sentence about what a peptide “does” can draw the FDA on the drug-status question and the FTC on the substantiation question at the same time.

The safer approach is to describe what the clinic does, not what the molecule promises. Talk about the consultation, the physician’s evaluation, and the individualized treatment plan rather than guaranteeing an outcome from a specific peptide. Avoid disease and recovery verbs (“heals,” “repairs,” “regenerates,” “treats”) attached to an unapproved product. If a product is being used off-label or as a compounded therapy, that context belongs to the physician’s clinical judgment and conversation with the patient, not to a marketing headline. You can browse more enforcement examples in the peptide category of the Atlas to see how regulators describe these claims in their own words.

Pattern 3: CGMP and sterility failures at the compounder behind the clinic

The third pattern is upstream of your copy but still lands on your doorstep. Many peptide clinics source from compounding outsourcing facilities. When one of those facilities fails current good manufacturing practice (CGMP) requirements or sterility checks, the FDA acts against the facility, and any clinic that marketed that product as “safe,” “sterile,” or “pharmacy-quality” now has copy that the public record contradicts.

That is the situation FDA described at GenoGenix LLC in January 2026, a compounding outsourcing facility cited for CGMP violations and sterility failures (Atlas entry). A clinic does not control another company’s manufacturing, but it does control whether its own marketing made safety guarantees on that company’s behalf.

The safer phrasing is to never guarantee the safety, sterility, or quality of a product you did not manufacture. Drop absolute words like “completely safe,” “100% sterile,” or “pharmacy-quality” from product descriptions. Instead, describe your own sourcing standards factually (for example, that you work with licensed outsourcing facilities) without promising an outcome you cannot verify. If a supplier’s compliance status changes, copy that made guarantees is the hardest to defend.

How to check your peptide copy

Most peptide-marketing problems are catchable before anything goes live. The fastest screen is to run your service pages and product descriptions through the free Claim Checker. It scans for the exact patterns above: supplement language on products that do not qualify, disease and recovery verbs attached to unapproved peptides, and absolute safety guarantees on compounded or sourced products. It flags the risky phrasing and suggests safer alternatives so you can fix copy before a regulator reads it.

Treat the checker as a screening tool, not a clearance. It will not tell you a page is “compliant,” because that judgment belongs to your clinic’s physician and your counsel. What it does is surface the language most likely to draw an FDA or FTC look, so your physician and legal review start from a cleaner draft. For the full picture across every claim category, not just peptides, see the pillar guide on the marketing claims that trigger FDA Warning Letters, then re-run your copy through the Claim Checker once you have made edits.

Frequently asked questions

Can I call a peptide a “dietary supplement” if a patient takes it by mouth?

No. The route of administration does not decide the category. “Dietary supplement” is a legal definition, and SARMs and most research peptides do not meet it, which the FDA has stated directly for SARMs in body-building products [5]. Once a product sits outside that definition and is marketed to affect the body’s structure or function, it meets the definition of a drug under Section 201(g) of the Food, Drug, and Cosmetic Act, and without approval it is an unapproved new drug [2]. Calling it a supplement on your site does not change its status; it just documents the mismatch.

Is it legal to market BPC-157 for healing or recovery?

Marketing any peptide for a specific therapeutic use implies a drug claim, and BPC-157 has no FDA approval to support claims like healing, repair, or recovery [2]. Stating those benefits without that approval, and without disclosing the lack of it, is the kind of unsubstantiated health claim the FTC acts on under its Health Products Compliance Guidance and its Section 5 authority [1][4]. The safer path is to describe your clinic’s evaluation and individualized care rather than promising what a specific molecule will do, and to leave off-label clinical decisions to the physician-patient conversation.

My compounder got an FDA letter. Does that affect my clinic’s marketing?

It can. If your marketing called the product “safe,” “sterile,” or “pharmacy-quality” and the supplier is later cited for CGMP or sterility failures, as FDA described at GenoGenix LLC, your copy now contradicts the public record [3]. You do not control another company’s manufacturing, but you do control your own claims. Removing absolute safety guarantees for products you did not manufacture protects you regardless of what happens upstream.

Does the Claim Checker make my pages compliant?

No, and it is built not to imply that. The Claim Checker is a screening tool that flags risky phrasing and suggests safer wording so you catch problems early. It does not provide legal or regulatory clearance. Your clinic’s physician and your counsel are the final gate on what you publish. The checker just gives them a cleaner starting point.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.
5. U.S. Food and Drug Administration. FDA In Brief: FDA warns against using SARMs in body-building products. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products . Accessed June 8, 2026.